SuppreMol launched as a new company
SuppreMol is working on the development of drugs for the treatment of autoimmune diseases and allergies through innovative therapeutic approaches centred on Fc -receptors. The development of these drugs is based on patent rights owned by the Max-Planck-Society and licensed to SuppreMol by the Society's Technology Transfer office, Garching Innovation. SuppreMol's principal objective is to prove the therapeutic efficacy of a soluble Fc receptor in the treatment of Idiopathic Thrombocytopenic Purpura, Systemic Lupus Erythematosus, Rheumatoid Arthritis and other autoimmune diseases.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.